Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study
Cells · 21.01.2025 · 14 (3) · 155
DOI: 10.3390/cells14030155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 21.01.2025. Verfasst von Justine Debatisse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London W12 0NN, UK. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Neurons, Cerebral Cortex. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Research UK, Medical Research Council, Alzheimer’s Research UK (ARUK).
Abstract (Originalsprache)
Pathological alterations in Alzheimer’s disease (AD) begin several years prior to symptom onset. Cortical mean diffusivity (cMD) may be used as a measure of early grey matter damage in AD as it reflects the breakdown of microstructural barriers preceding volumetric changes and affecting cognitive function. We investigated cMD changes early in the disease trajectory and evaluated the influence of amyloid-β (Aβ) and tau deposition. In this cross-sectional study, we analysed multimodal PET, DTI, and MRI data of 87 participants, and stratified them into Aβ-negative and -positive, cognitively normal, mildly cognitively impaired, and AD patients. cMD was significantly increased in Aβ-positive MCI and AD compared with CN in the frontal, parietal, temporal cortex, hippocampus, and medial temporal lobe. cMD was significantly correlated with cortical thickness only in patients without Aβ deposition but not in Aβ-positive patients. Our results suggest that cMD is an early marker of neuronal damage since it is observed simultaneously with Aβ deposition and is correlated with cortical thickness only in subjects without Aβ deposition. cMD changes may be driven by Aβ but not tau, suggesting that direct Aβ toxicity or associated inflammation causes damage to neurons. cMD may provide information about early microstructural changes before macrostructural changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London W12 0NN, UK.
- School of Medicine, Cardiff University, Wales CF14 4YS, UK.
ORCID-Profile: Justine Debatisse
Förderung
- Alzheimer's Research UK
- Medical Research Council
- Alzheimer’s Research UK (ARUK)
- Higher Education Funding Council for England (HEFCE)
- Alzheimer’s Drug Discovery Foundation
- Alzheimer’s Society, UK
- Alzheimer’s Association, US
- Novo Nordisk
Zitieren
APA
Debatisse, J., Leng, F., Ashraf, A., & Edison, P. (2025). Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study. Cells, 14(3), 155. https://doi.org/10.3390/cells14030155
Vancouver
Debatisse J, Leng F, Ashraf A, Edison P. Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study. Cells. 2025;14(3):155. doi:10.3390/cells14030155
BibTeX
@article{Debatisse2025,
author = {Debatisse, Justine and Leng, Fangda and Ashraf, Azhaar and Edison, Paul},
title = {Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study},
journal = {Cells},
year = {2025},
volume = {14},
number = {3},
pages = {155},
doi = {10.3390/cells14030155}
}
EUVIMED